Assessment of Change in Atherosclerotic Plaque by Serial CCTA
NCT ID: NCT03414840
Last Updated: 2018-06-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
400 participants
OBSERVATIONAL
2018-04-01
2020-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin
Patients diagnosed with coronary artery disease by CCTA be enrolled. Among enrolled patients, patients who is indicated to statin treatment according to the current ACC/AHA guideline will be treated with atorvastatin.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mild to moderate stenosis (25-69%) on CCTA
* ≥1 clinical risk factors (Smoking, HTN, HDL\<40, Premature FHx, M ≥45, F ≥55) for CAD
Exclusion Criteria
* Positive (not equivocal) stress test
* Contraindications to statin
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chong Kun Dang Pharmaceutical Corp.
INDUSTRY
Yonsei University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hyuk-Jae Chang
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hyuk-Jae Chang, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Yonsei University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Severance Cardiovascular Hospital, Yonsei University College of Medicine
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hyuk-Jae Chang, MD, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-2669-001
Identifier Type: -
Identifier Source: org_study_id